Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33990984,t1/2,"After intravenous infusion, RDV is rapidly metabolized (t1/2 = 1 h) within the cells to its active adenosine triphosphate analogue form (GS-443902) and then it can be found in plasma in its nucleoside analogue form (GS-441524).",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,1,1908,DB00131,Adenosine monophosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],<,1909,DB00131,Adenosine monophosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1910,DB00131,Adenosine monophosphate
,33990984,Cmin,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1911,DB00131,Adenosine monophosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],0.24,1912,DB00131,Adenosine monophosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],122.3,1913,DB00131,Adenosine monophosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2637.3,1914,DB00131,Adenosine monophosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1915,DB00131,Adenosine monophosphate
,33990984,Cmax,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],5171.2,1916,DB00131,Adenosine monophosphate
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],157.8,1917,DB00131,Adenosine monophosphate
,33990984,AUC0-24,"The mean Cmin , Cmax and AUC0-24 , were < 0.24 ng/mL and 122.3 ng/mL, 2637.3 ng/mL and 157.8 ng/mL, and 5171.2 ng*h/mL and 3676.5 ng*h/ml, respectively, for RDV and GS-441524.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],3676.5,1918,DB00131,Adenosine monophosphate
>,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],2610,1919,DB00131,Adenosine monophosphate
,33990984,Cmax,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[ng] / [ml],140,1920,DB00131,Adenosine monophosphate
>,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],1560,1921,DB00131,Adenosine monophosphate
,33990984,AUC0-24,"Three out of nine patients achieved a Cmax > 2610 ng/mL and 140 ng/mL and AUC0-24 > 1560 ng*h/mL and 2230 ng*h/mL for RDV and GS-441524, respectively.",Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),[h·ng] / [ml],2230,1922,DB00131,Adenosine monophosphate
,33990984,t1/2,The mean t1/2 value for GS-441524 was 26.3 h.,Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990984/),h,26.3,1923,DB00131,Adenosine monophosphate
,171373,Plasma half-lives,Plasma half-lives in dogs were about 3 hr after oral or intravenous doses of 0.25 or 2.5 mg/kg and ranged from 5 to 12 hr after oral or intravenous doseas of 50 mg/kg.,"Metabolism of 8-(methylthio)cyclic 3',5'-adenosine monophosphate by rats and dogs after oral or intravenous dosing and in vitro by subcellular preparations of dog liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/171373/),h,3,10613,DB00131,Adenosine monophosphate
,171373,Plasma half-lives,Plasma half-lives in dogs were about 3 hr after oral or intravenous doses of 0.25 or 2.5 mg/kg and ranged from 5 to 12 hr after oral or intravenous doseas of 50 mg/kg.,"Metabolism of 8-(methylthio)cyclic 3',5'-adenosine monophosphate by rats and dogs after oral or intravenous dosing and in vitro by subcellular preparations of dog liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/171373/),h,5 to 12,10614,DB00131,Adenosine monophosphate
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],1320,20838,DB00131,Adenosine monophosphate
,7624261,oral clearance,"Mean oral clearance values for S- and R-metoprolol were 1320 and 2346 ml/minute, respectively.","Lymphocyte beta 2-receptor activity, metoprolol kinetics, and response to metoprolol in hypertensive black men. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624261/),[ml] / [min],2346,20839,DB00131,Adenosine monophosphate
,29577579,half-life,The estimated half-life of Fc-apelin-13 in blood was approximately 33 hours.,Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29577579/),h,33,22691,DB00131,Adenosine monophosphate
,3960017,renal clearance,"However, the WKY had a significantly greater renal clearance of 45Ca than the SHR (0.48 +/- 0.04 vs. 0.24 +/- 0.02 ml/n, p less than 0.001).",Pathogenesis of hypercalciuria in spontaneously hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3960017/),[ml] / [n],0.48,26417,DB00131,Adenosine monophosphate
,3960017,renal clearance,"However, the WKY had a significantly greater renal clearance of 45Ca than the SHR (0.48 +/- 0.04 vs. 0.24 +/- 0.02 ml/n, p less than 0.001).",Pathogenesis of hypercalciuria in spontaneously hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3960017/),[ml] / [n],0.24,26418,DB00131,Adenosine monophosphate
,8227467,apparent t1/2,"The postinfusion total 14C concentrations in plasma declined in a multiexponential manner, and the terminal phase had an apparent t1/2 of about 1 week.",Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227467/),week,1,30051,DB00131,Adenosine monophosphate
,8227467,Total plasma clearance,"Total plasma clearance was 2.2 +/- 0.2 L/hour/kg, the acadesine blood/plasma ratio was unity, and plasma protein binding was negligible (approximately 1%).",Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227467/),[l] / [h·kg],2.2,30052,DB00131,Adenosine monophosphate
,1966907,FEV1,"Their mean baseline FEV1 was 83.8% of the predicted value, geometric mean (GM) PC20 FEV1 histamine 0.33 mg/ml (range 0.03-4.0), and GM PC50 baseline sGaw AMP 4.37 mg/ml (range 0.158-26.38).","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],0.33,35537,DB00131,Adenosine monophosphate
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],28.84,35538,DB00131,Adenosine monophosphate
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],7.24,35539,DB00131,Adenosine monophosphate
,1966907,PC50 sGaw AMP,"The GM PC50 sGaw AMP determined after inhaled, oral and intravenous nedocromil sodium was 28.84, 7.24 and 7.94 mg/ml respectively.","The protective efficacy of inhaled, oral and intravenous nedocromil sodium against adenosine-5'-monophosphate-induced bronchoconstriction in asthmatic volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1966907/),[mg] / [ml],7.94,35540,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.12,35902,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.28,35903,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.22,35904,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.85,35905,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.65,35906,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),d,1.75,35907,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.40,35908,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.43,35909,DB00131,Adenosine monophosphate
,6286526,half-lives,"Those on their initial course of lithium had the lowest half-lives (in days): 1.12 (urine), 1.28 (plasma), and 1.22 (red blood cells); those with less than 1 year of lithium had intermediate values: 1.85, 1.65, and 1.75, and those with more than 1 year of continuous lithium administration had the highest mean half-lives: 2.40, 2.43, and 2.24.","Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6286526/),,2.24,35910,DB00131,Adenosine monophosphate
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,6.02,38032,DB00131,Adenosine monophosphate
,30076448,Ki,"ASP7657 exhibited high affinity for rat and human EP4 receptors, with Ki values of 6.02 nM and 2.21 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,2.21,38033,DB00131,Adenosine monophosphate
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.86,38034,DB00131,Adenosine monophosphate
,30076448,IC50,"In addition, ASP7657 potently inhibited the PGE2-induced cyclic adenosine monophosphate (cAMP) increase in Chinese hamster ovary (CHO) cells expressing rat EP4 receptors and human lymphoblastoid T (Jurkat) cells, with IC50 values of 0.86 nM and 0.29 nM, respectively.","Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30076448/),nM,0.29,38035,DB00131,Adenosine monophosphate
,9533533,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],47,43981,DB00131,Adenosine monophosphate
,9533533,AUC,"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],22,43982,DB00131,Adenosine monophosphate
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,15,43983,DB00131,Adenosine monophosphate
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,10,43984,DB00131,Adenosine monophosphate
,9533533,terminal t(1/2),The median terminal t(1/2) of CdA in plasma was 21 h.,Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,21,43985,DB00131,Adenosine monophosphate
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.26,49026,DB00131,Adenosine monophosphate
,9145874,50% inhibitory concentration [IC50],"1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,0.23,49027,DB00131,Adenosine monophosphate
,9145874,Ki,"The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM).","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),nM,21,49028,DB00131,Adenosine monophosphate
,9145874,IC50s,"1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines.","1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),μM,110,49029,DB00131,Adenosine monophosphate
,9145874,oral bioavailability,1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT.,"1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9145874/),%,105,49030,DB00131,Adenosine monophosphate
,25384088,IC50,Our optimization efforts using structure-based drug design (SBDD) techniques on the basis of the X-ray crystal structure of PDE10A in complex with hit compound 1 (IC50 = 23 nM; 110-fold selectivity over other PDEs) led to the identification of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (27h).,"Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),nM,23,53376,DB00131,Adenosine monophosphate
,25384088,IC50,"Compound 27h has potent inhibitory activity (IC50 = 0.30 nM), excellent selectivity (>15000-fold selectivity over other PDEs), and favorable pharmacokinetics, including high brain penetration, in mice.","Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),nM,0.30,53377,DB00131,Adenosine monophosphate
,25384088,minimum effective dose (MED),"Oral administration of compound 27h to mice elevated striatal 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP) levels at 0.3 mg/kg and showed potent suppression of phencyclidine (PCP)-induced hyperlocomotion at a minimum effective dose (MED) of 0.3 mg/kg.","Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25384088/),[mg] / [kg],0.3,53378,DB00131,Adenosine monophosphate
,24802860,t½,"After administration of rhPTH(1-84) 50 µg (n = 6) and 100 µg (n = 7), the approximate t½ was 2.5 to 3 hours.","Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802860/),h,2.5 to 3,56560,DB00131,Adenosine monophosphate
,12172971,peak,"In rats, [(3)H]8-Cl-AMP concentrations in PBMC were similar to those of the triphosphate metabolite which achieved a peak of 90 micro M 2 h after a bolus injection of 8-Cl-Ado (40 mg/kg).",Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172971/),μM,90,58665,DB00131,Adenosine monophosphate
more,28619366,half-life,"In in vivo pharmacokinetic study, the half-life of BPI-3016 was more than 95h after single dosing in diabetic cynomolgus monkeys.","BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28619366/),h,95,73759,DB00131,Adenosine monophosphate
,1699279,t1/2 alpha,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),min,4.97,77345,DB00131,Adenosine monophosphate
,1699279,t1/2 beta,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,1.38,77346,DB00131,Adenosine monophosphate
,1699279,t1/2 gamma,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.41,77347,DB00131,Adenosine monophosphate
,1699279,mean residence time,"The 2-F-ara-A harmonic mean half-lives were t1/2 alpha = 4.97 minutes, t1/2 beta = 1.38 hours, t1/2 gamma = 10.41 hours, and the mean residence time was 10.51 hours.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),h,10.51,77348,DB00131,Adenosine monophosphate
,1699279,total-body plasma clearance,The mean total-body plasma clearance was 67.98 +/- 19.58 mL/min/m2 (mean +/- SD).,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[ml] / [m2·min],67.98,77349,DB00131,Adenosine monophosphate
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],7.49,77350,DB00131,Adenosine monophosphate
,1699279,central compartment volume of distribution (V1),The mean central compartment volume of distribution (V1) was 7.49 L/m2 or 0.20 L/kg.,Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],0.20,77351,DB00131,Adenosine monophosphate
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [m2],44.17,77352,DB00131,Adenosine monophosphate
,1699279,steady-state volume of distribution (Vdss),"The mean steady-state volume of distribution (Vdss) was 44.17 L/m2 or 1.19 L/kg, indicating that 2-F-ara-A is distributed and bound to the tissues of the body.",Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1699279/),[l] / [kg],1.19,77353,DB00131,Adenosine monophosphate
,8593479,Km,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [ml],1.69,90734,DB00131,Adenosine monophosphate
,8593479,Vmax,"The degradation of Ap4A in rat plasma was very rapid and could be explained by a Michaelis-Menten equation: Km and Vmax values were 1.69 micrograms/ml and 4.32 micrograms/min/ml, respectively.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),[μg] / [min·ml],4.32,90735,DB00131,Adenosine monophosphate
,8593479,biological half-life,"After intravenous bolus injection, Ap4A in plasma declined rapidly and the rate of elimination was dose-dependent: the biological half-life was about 3s at the dose of 1 mg/kg and was longer at 3 mg/kg.","Disposition of diadenosine 5',5""'-P1,P4-tetraphosphate (Ap4A) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8593479/),s,3,90736,DB00131,Adenosine monophosphate
,33835812,A2,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104512,DB00131,Adenosine monophosphate
,33835812,EC50,A discovery program targeting respiratory syncytial virus (RSV) identified C-nucleoside 4 (RSV A2 EC50 = 530 nM) as a phenotypic screening lead targeting the RSV RNA-dependent RNA polymerase (RdRp).,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33835812/),nM,530,104513,DB00131,Adenosine monophosphate
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],45.97,111701,DB00131,Adenosine monophosphate
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],39.23,111702,DB00131,Adenosine monophosphate
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],17.97,111703,DB00131,Adenosine monophosphate
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,9,112236,DB00131,Adenosine monophosphate
,33404204,minimum lung intracellular TN concentrations,"Finally, clinical multiple-dose regimens indicated that minimum lung intracellular TN concentrations ranged from ~ 9 uM to 4 uM, which suggest current regimens are effective based on in vitro half-maximal effective concentration values.",Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33404204/),uM,4,112237,DB00131,Adenosine monophosphate
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,2.3,116519,DB00131,Adenosine monophosphate
,32607555,BAS/plasma concentration ratios,"Mean BAS/plasma concentration ratios of GS-441524 were 2.3% and 6.4% in Patient 1 and Patient 2, respectively.",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32607555/),%,6.4,116520,DB00131,Adenosine monophosphate
,8740794,Steady state plasma levels (Css),Steady state plasma levels (Css) of 8-Cl-cAMP in patients ranged from 0.15-0.72 microM but 8-Cl-adenosine was not detected in plasma.,"Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,0.15-0.72,120488,DB00131,Adenosine monophosphate
,8740794,Css,"In mice, Css of 8-Cl-cAMP ranged from 3.2-4.6 microM and 8-Cl adenosine was present in plasma only at the higher dose (100 mg/kg/day, peak concentration of 2.3 microM).","Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,3.2-4.6,120489,DB00131,Adenosine monophosphate
,8740794,peak concentration,"In mice, Css of 8-Cl-cAMP ranged from 3.2-4.6 microM and 8-Cl adenosine was present in plasma only at the higher dose (100 mg/kg/day, peak concentration of 2.3 microM).","Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8740794/),μM,2.3,120490,DB00131,Adenosine monophosphate
,8472722,half-life,A peak concentration is reached 1.5 h after drug intake; elimination from the plasma compartment has a half-life of 1.5 h.,"Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8472722/),h,1.5,132125,DB00131,Adenosine monophosphate
less,1551186,half-life,Thus a single dose of ATP-MgCl2 has a half-life of less than 40 sec as ATP.,Clearance and maintenance of blood nucleotide levels with adenosine triphosphate-magnesium chloride injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551186/),s,40,132296,DB00131,Adenosine monophosphate
,28987606,bioavailability,"In addition, compounds 4bq and 4bv were found to possess improved pharmacokinetic profiles (bioavailability 45 and 106%, respectively) compared to berberine.","Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),%,45,148110,DB00131,Adenosine monophosphate
,28987606,bioavailability,"In addition, compounds 4bq and 4bv were found to possess improved pharmacokinetic profiles (bioavailability 45 and 106%, respectively) compared to berberine.","Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),%,106,148111,DB00131,Adenosine monophosphate
>,28987606,IC50,Compounds 4bq and 4bv exhibited no obvious hERG inhibition (IC50 > 10 μM).,"Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987606/),μM,10,148112,DB00131,Adenosine monophosphate
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],6.1,149997,DB00131,Adenosine monophosphate
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],3.3,149998,DB00131,Adenosine monophosphate
,1318809,ED50,"3. When theophylline, enprofylline and 1-methyl-3-propylxanthine (MPX) were injected intravenously in guinea-pigs, their ED50 values were 6.1, 3.3 and 1.0 mg/kg, respectively.",Bronchodilatory activity and pharmacokinetics of new xanthines in guinea-pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1318809/),[mg] / [kg],1.0,149999,DB00131,Adenosine monophosphate
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,2.3,151330,DB00131,Adenosine monophosphate
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,6.2,151331,DB00131,Adenosine monophosphate
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],1.9,151332,DB00131,Adenosine monophosphate
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],2.7,151333,DB00131,Adenosine monophosphate
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],18.2,151334,DB00131,Adenosine monophosphate
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,644,151335,DB00131,Adenosine monophosphate
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,576,151336,DB00131,Adenosine monophosphate
,12242461,AUC,"ml(-1) x min, respectively) compared with native GIP (AUC, 257+/-29 ng.ml(-1) x min).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[min·ng] / [ml],257,151337,DB00131,Adenosine monophosphate
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,292.2,154091,DB00131,Adenosine monophosphate
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,163.2,154092,DB00131,Adenosine monophosphate
,34302183,m/,Multiple reaction monitoring transitions in electrospray positive ion mode were m/z 292.2 → 163.2 for Nuc and 237.1 → 194.1 for the internal standard (carbamazepine).,"Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34302183/),,237.1,154093,DB00131,Adenosine monophosphate
,10430069,maximum tolerated dose,"The maximum tolerated dose for this regimen was 0.15 mg/kg/h, and the dose-limiting toxicities were reversible hypercalcemia and hepatotoxicity.","Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430069/),mg,0,156313,DB00131,Adenosine monophosphate
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.0375,159981,DB00131,Adenosine monophosphate
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],0.375,159982,DB00131,Adenosine monophosphate
,33864090,limits of detection,"The method has limits of detection of 0.0375 ng/mL for remdesivir, 0.375 ng/mL for GS-441524 and 3.75 ng/mL for dexamethasone.","A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33864090/),[ng] / [ml],3.75,159983,DB00131,Adenosine monophosphate
,4357610,plasma clearance rates,The plasma clearance rates (PCR) were 271+/-27 ml/min (mean+/-SE) for cGMP and 261+/-17 for cAMP.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],271,172727,DB00131,Adenosine monophosphate
,4357610,plasma clearance rates,The plasma clearance rates (PCR) were 271+/-27 ml/min (mean+/-SE) for cGMP and 261+/-17 for cAMP.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),,261,172728,DB00131,Adenosine monophosphate
,4357610,urinary clearances,The urinary clearances of (3)H-labeled cGMP (40.9+/-4.2 ml/min) and endogenous cGMP (45.0+/-2.3 ml/min) were not significantly different from each other.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],40.9,172729,DB00131,Adenosine monophosphate
,4357610,urinary clearances,The urinary clearances of (3)H-labeled cGMP (40.9+/-4.2 ml/min) and endogenous cGMP (45.0+/-2.3 ml/min) were not significantly different from each other.,Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],45.0,172730,DB00131,Adenosine monophosphate
,4357610,urinary clearances,"In contrast, the urinary clearances of (3)H-labeled cAMP (23.7+/-1.9 ml/min) and endogenous cAMP (27.2+/-2.6 ml/min) were nearly equal both to each other and to the glomerular filtration rate, which was 24.6+/-1.7 ml/min.",Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],23.7,172731,DB00131,Adenosine monophosphate
,4357610,urinary clearances,"In contrast, the urinary clearances of (3)H-labeled cAMP (23.7+/-1.9 ml/min) and endogenous cAMP (27.2+/-2.6 ml/min) were nearly equal both to each other and to the glomerular filtration rate, which was 24.6+/-1.7 ml/min.",Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4357610/),[ml] / [min],27.2,172732,DB00131,Adenosine monophosphate
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,4558,178766,DB00131,Adenosine monophosphate
,33041326,area under the concentration versus time curve up to the last measured point in time (AUC0-t),"The area under the concentration versus time curve up to the last measured point in time (AUC0-t) values of RMP and RN were 4558 and 136,572 h∙nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),h∙nM,"136,572",178767,DB00131,Adenosine monophosphate
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,2896,178768,DB00131,Adenosine monophosphate
,33041326,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) values of RMP and RN were 2896 nM and 35,819 nM, respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),nM,"35,819",178769,DB00131,Adenosine monophosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1740,178770,DB00131,Adenosine monophosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],1253,178771,DB00131,Adenosine monophosphate
,33041326,intrinsic clearance (CLint),"RDV showed higher clearances in the liver and kidney than in the lung, with intrinsic clearance (CLint) values of 1740, 1253, and 127 mL/(min∙g microsomal protein), respectively.","Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33041326/),[ml] / [min∙g],127,178772,DB00131,Adenosine monophosphate
,15937757,terminal elimination half-life,The mean terminal elimination half-life ranged from 15 to 19 days.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),d,15 to 19,185338,DB00131,Adenosine monophosphate
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,50,185339,DB00131,Adenosine monophosphate
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,71,185340,DB00131,Adenosine monophosphate
,15937757,bioavailability,The bioavailability of PAmAb is approximately 50% for IM-GM injection and 71%-85% for IM-VL injection.,"A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15937757/),%,85,185341,DB00131,Adenosine monophosphate
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32-35,191092,DB00131,Adenosine monophosphate
,32501511,unbound plasma concentration,Geometric mean-simulated average unbound plasma concentration values among children within different developmental age groups (32-35 ng/mL) were congruent to adults (32 ng/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[ng] / [ml],32,191093,DB00131,Adenosine monophosphate
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4315-5027,191094,DB00131,Adenosine monophosphate
,32501511,plasma area under the time curve 0 to infinity,Geometric mean-simulated plasma area under the time curve 0 to infinity values among children within different developmental age-groups (4315-5027 ng × h/mL) were similar to adults (4398 ng × h/mL).,Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32501511/),[h·ng] / [ml],4398,191095,DB00131,Adenosine monophosphate
,16371327,Peak plasma concentrations,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),μM,50,207769,DB00131,Adenosine monophosphate
,16371327,half-lives for elimination,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),h,2.5-10,207770,DB00131,Adenosine monophosphate
,2037706,t1/2 beta,"The post-infusion plasma concentrations of AICA-riboside declined rapidly in a biphasic fashion, and the terminal elimination phase had a harmonic mean t1/2 beta of 1.4 hours.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),h,1.4,213336,DB00131,Adenosine monophosphate
,2037706,Total plasma clearance (CL),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [h·kg],2.5,213337,DB00131,Adenosine monophosphate
,2037706,mean residence time (MRTIV),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),h,0.7,213338,DB00131,Adenosine monophosphate
,2037706,volume of distribution at steady-state (VSS),"Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively.","AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [kg],1.6,213339,DB00131,Adenosine monophosphate
,2037706,Renal clearance (CLR),Renal clearance (CLR) was 0.2 L/hr/kg with only 8% of the IV dose excreted in the urine as intact AICA-riboside.,"AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),[l] / [h·kg],0.2,213340,DB00131,Adenosine monophosphate
less,2037706,bioavailable,The drug was poorly bioavailable (less than 5%) when administered orally in solution.,"AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037706/),%,5,213341,DB00131,Adenosine monophosphate
,8924915,biological half-life,"After intravenous bolus injection, APS in plasma declined rapidly and the rate of elimination was dose-dependent: the biological half-life was about 2s at the dose of 0.3 mg/kg and was longer at 3 mg/kg.",Disposition of intravenously administered adenosine 5'-phosphosulfate (APS) in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924915/),s,2,235773,DB00131,Adenosine monophosphate
exceeding,33962189,recoveries,"Using a simple protein precipitation method, quantitation of these analytes was accomplished with recoveries exceeding 85% and with a run time of 4 min.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),%,85,240234,DB00131,Adenosine monophosphate
,33962189,run time,"Using a simple protein precipitation method, quantitation of these analytes was accomplished with recoveries exceeding 85% and with a run time of 4 min.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),min,4,240235,DB00131,Adenosine monophosphate
,33962189,half-life,"TCNP accumulates in RBC, has low clearance and a half-life of 18 to 23 h.",Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962189/),h,18 to 23,240236,DB00131,Adenosine monophosphate
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00131,Adenosine monophosphate
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00131,Adenosine monophosphate
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00131,Adenosine monophosphate
,18321039,K(i),"This effort has led to the discovery of compound 62, that displayed high affinity and selectivity for the hA(2B)-AdoR (K(i) = 22 nM).",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,22,252373,DB00131,Adenosine monophosphate
,18321039,K(B),"In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcarboxamidoadenosine in HEK-A(2B)-AdoR and NIH3T3 cells with K(B) values of 6 and 2 nM, respectively.",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,6,252374,DB00131,Adenosine monophosphate
,18321039,K(B),"In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5'- N-ethylcarboxamidoadenosine in HEK-A(2B)-AdoR and NIH3T3 cells with K(B) values of 6 and 2 nM, respectively.",Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321039/),nM,2,252375,DB00131,Adenosine monophosphate
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2·kg],826,257963,DB00131,Adenosine monophosphate
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2o·kg],920,257964,DB00131,Adenosine monophosphate
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-1.40,257965,DB00131,Adenosine monophosphate
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-,257966,DB00131,Adenosine monophosphate
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],1.63,257967,DB00131,Adenosine monophosphate
,3147196,V2,"Seven atopic asthmatic subjects (age 25 +/- 2 yrs) inhaled dry powder SCG from a Spinhaler on separate occasions at three flow rates, maximum (V1), 100 l.min-1 (V2), and 50 l.min-1 (V3), or placebo, according to a double-blind structured study.",Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147196/),[l] / [min],100,265156,DB00131,Adenosine monophosphate
,3147196,V3,"Seven atopic asthmatic subjects (age 25 +/- 2 yrs) inhaled dry powder SCG from a Spinhaler on separate occasions at three flow rates, maximum (V1), 100 l.min-1 (V2), and 50 l.min-1 (V3), or placebo, according to a double-blind structured study.",Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147196/),[l] / [min],50,265157,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,96.0,268604,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,94.9,268605,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,98.7,268606,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268607,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268608,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268609,DB00131,Adenosine monophosphate
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9.5,268610,DB00131,Adenosine monophosphate
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,14.0,268611,DB00131,Adenosine monophosphate
,11307804,BT,"At 24 h, mean inhibition of PA was 96.0 +/- 8.6, 94.9 +/- 14.4 and 98.7 +/- 2.1% and BT was 9.5 +/- 8.4, 14.0 +/- 9.7 and 16.0 +/- 11.1 min for Parts 1, 2 and 3 respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,16.0,268612,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,36.2,268613,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,20.7,268614,DB00131,Adenosine monophosphate
,11307804,inhibition,"At 1 h post-infusion, mean inhibition of PA was 36.2 +/- 39.2, 20.7 +/- 25.9 and 40.7 +/- 36.7% respectively.","Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),%,40.7,268615,DB00131,Adenosine monophosphate
<,11307804,plasma half-life,90% patients had a plasma half-life for AR-C69931XX of <9 min.,"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307804/),min,9,268616,DB00131,Adenosine monophosphate
,16423907,impedance,Mean (SD) impedance of the healthy cohort was 12.2 (2.2) Omega.,Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,12.2,268825,DB00131,Adenosine monophosphate
<,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268826,DB00131,Adenosine monophosphate
>,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268827,DB00131,Adenosine monophosphate
,9084461,Serum terminal half-life,Serum terminal half-life of PTH(1-84) was approximately 2 1/2 hours.,Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084461/),h,2 1/2,273436,DB00131,Adenosine monophosphate
